Bafna Pharmaceuticals (BAFNAPH) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
11 Aug, 2026Executive summary
Unaudited financial results for the quarter ended June 30, 2026, were approved and reviewed by the Board and statutory auditors.
Revenue from operations for Q1 FY27 was INR 2,658.32 lakhs, down from INR 3,462.40 lakhs year-over-year and INR 4,223.93 lakhs sequentially.
Net profit for the quarter was INR 7.51 lakhs, compared to INR 338.89 lakhs in Q1 FY26 and INR 274.91 lakhs in Q4 FY26.
Financial highlights
Total income for Q1 FY27 was INR 2,849.42 lakhs, compared to INR 3,521.96 lakhs in Q1 FY26 and INR 4,400.09 lakhs in Q4 FY26.
Total expenses for Q1 FY27 were INR 2,841.91 lakhs, compared to INR 3,183.07 lakhs in Q1 FY26 and INR 4,138.14 lakhs in Q4 FY26.
Basic and diluted EPS for Q1 FY27 stood at INR 0.03, down from INR 1.43 in Q1 FY26 and INR 1.16 in Q4 FY26.
Outlook and guidance
Management remains confident regarding ongoing GST disputes and does not anticipate adverse financial outcomes.
Latest events from Bafna Pharmaceuticals
- FY26 net profit more than doubled year-over-year, with strong revenue growth and clean audit.BAFNAPH
Q4 25/26 - Quarterly revenue and profit increased year-over-year, with key tax and GST risks under appeal.BAFNAPHQ3 2026
- Q2 FY26 profit increased to ₹312.49 lakhs, with revenue at ₹3,546.82 lakhs and higher EPS.BAFNAPHQ2 25/26
- Returned to profitability with higher revenue and completed key asset sale in the quarter.BAFNAPHQ1 25/26
- Q2 FY25 saw higher revenue and profit, but compliance and receivable risks persist.BAFNAPHQ2 24/25
- Q1 FY25 posted a net loss and lower revenue, with compliance and receivable risks highlighted.BAFNAPHQ1 24/25
- Net profit fell despite higher revenue, with key assets held for sale and compliance milestones met.BAFNAPHQ4 24/25
- Q3 FY25 marked a return to profitability with higher revenue and no outstanding debt.BAFNAPHQ3 2025